Abstract Introduction: Recent research has highlighted the role of gut microbiota in producing bioactive metabolites that interact with G-protein coupled receptors (GPRs) and influence immune responses. Lauroyl tryptamine (LT), a metabolite produced by Agathobacter rectalis (formerly Eubacterium rectale), has been reported to antagonize GPR183, a receptor implicated in inflammatory bowel diseases (IBD). LT inhibits the binding of GPR183 with its natural ligands 7a,25-dihydroxycholesterol (OHC).
